ASCO 2020：11项中国研究入选口头调查结果，17项Poster调查结果

受全球新冠疫情严重影响，原定于5年末29日~6年末2日在芝加哥举行的美国诊断学会（ASCO）年会本年将首次以线上形式举办，这是目前最大规模的线上文化节。今天，开会的内容可出题揭晓，共约103个sessions，当中国人总计11项学术研究入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或卡马替尼加卡培他中洲主要用途HER2+乳腺乳癌乳腺乳癌（PHOEBE）：一项III期随机试验当中。

嘉年华：乳腺乳癌乳腺乳癌

著者：当中国人医学科学院医务人员徐兵河博士、马飞博士，南开大学另设医务人员胡夕春博士等

内容可号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三特征性乳腺乳癌标准低剂量后卡培他中洲维持拍子低剂量的III期试验当中（SYSUCC-001）。

嘉年华：乳腺乳癌—渐进/地区/辅助低剂量

著者：当大同大学公共约卫生当一个中心王树森博士等

内容可号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

运用乳腺乳癌脑的表型特征来预测脑脊液当中反应器DNA验证的概率: 新来进行对抗来由击倒

嘉年华：新来进行解决来由问题

著者：陈美芹 陈德兰等

内容可号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对瓦努阿图拉非尼作为后半期脾脏膜乳癌的预备队低剂量：一项新开标签、随机、多当一个中心II/III期试验当中。

嘉年华：小肠肠道乳癌—小肠冠状动脉、肾上腺和绝

著者：四川大学索科利夫卡医务人员毕锋博士、当中国人人民解放军八一医务人员秦叔逵博士等

内容可号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

当中国人后半期脾乳癌病症阿帕替尼防区低剂量：一项随机、安慰剂比对、双盲III期学术研究

嘉年华：小肠肠道乳癌—小肠冠状动脉、肾上腺和绝

著者：当中国人人民解放军八一医务人员秦叔逵博士、四川大学索科利夫卡医务人员陈秋博士等

内容可号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后半期膀胱乳癌卵巢乳癌二次细胞膜减灭术的一项随机III期试验当中：SOC1 / SGOG-OV2。

时事：小儿乳腺乳癌

著者：南开大学另设当大同医务人员臧荣余博士等

内容可：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈乳癌根治性阴囊抽脂后辅助低剂量当中的序贯放低剂量对比单独恶性肿糙或不间断放低剂量（STARS学术研究）：一项随机、比对、新开标签的III期试验当中。

开会：小儿乳腺乳癌

著者：当大同大学公共约卫生当一个中心马尔季尼夫卡博士、刘继红博士等

内容可号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：辅助吉非替尼对比低剂量主要用途可切除的EGFR变异的N1-N2期NSCLC-随机III期诊断试验当中的最终总体生存分析方法。

时事：膀胱乳癌—非小细胞膜渐进-地区/小细胞膜/其他头部

著者：广东省人民医务人员吴一龙博士等

内容可号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR变异唯移到非小细胞膜膀胱乳癌病症预备队代谢物激酶胺牵头或不牵头积极主力部队渐进恶性肿糙：III期新开标签诊断随机试验当中（SINDAS）的当后半期结果（NCT02893332）。

时事：膀胱乳癌-非小细胞膜移到

著者：四川省人民医务人员曾铭博士等

内容可：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序性死亡-1（PD-1）的人源化IgG4化学合成牵头阿昔替尼主要用途乳腺乳癌肺部阿兹海默病症的Ib期学术研究的总生存期和人类标志物分析方法。

时事：阿兹海默/皮肤乳癌

著者：南开大学医务人员郭军、盛锡楠博士等

内容可：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的可用性和结果：国际标准化组织CAR-T细胞膜首次体液试验当中低剂量复发/难治性T细胞膜急性白血球膜乳腺乳癌（r/r T-ALL）的可用性和。开会：技术开发当中的低剂量技术-免疫低剂量。著者：王后林等内容可：3013剧照：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在后半期冠状动脉点状细胞膜乳癌病症当中的运用：一项随机的新开标签II期试验当中（ORIENT-2）。开会：小肠肠道乳癌-小肠冠状动脉乳癌、心肌梗塞和绝道乳癌著者：徐建明博士等内容可：4511剧照：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D基因表达CAR-T细胞膜对髓母细胞膜糙的扫除性低剂量开会：当中枢神经系统著者：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、赵旭东内容可：2522剧照。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后半期错配修复缺陷病症当中的运用开会：技术开发当中的低剂量学-免疫低剂量著者：沈琳博士等内容可：3021剧照。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 其会CD7-CART低剂量复发/难治性ACUTE白血球膜乳腺乳癌/化学疗法的元年末体液诊断试验当中开会: 技术开发性低剂量学-免疫低剂量著者简介：张明志，板桥乡等内容可：3026剧照: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 诺维奇替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度咪唑（T）牵头应主要用途后半期本体糙病症的Ib期学术研究开会：发展性低剂量学--分子特异性药物和人类科学著者：龚继芳，沈琳博士等内容可：3523剧照：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin牵头嘌呤和nedaplatin低剂量膀胱乳癌或乳腺乳癌冠状动脉点状细胞膜乳癌（ESCC）病症的II期学术研究。开会：小肠肠道乳癌-小肠冠状动脉、肾上腺和绝道乳癌的学术研究著者：王志极强，陈玉红，王德申，王凤华，任超，谭琼 王志极强、陈玉红、王德深、王凤华、任超、谭琼内容可：4522剧照：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.开会：小肠肠道乳癌-小肠冠状动脉乳癌、心肌梗塞和绝管乳癌的防区低剂量著者：宋艳等内容可：4524剧照：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体环状RNA分类器主要用途初始活检时验证高等级乳癌的尿液外体环状RNA分类器：一项多当一个中心的回顾性学术研究开会：反应器系统生殖系统乳腺乳癌；还有乳癌、皮肤乳癌和乳癌著者简介：Liaoyuan Li等内容可：5522剧照。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 渐进后半期宫颈乳癌并发低剂量后的辅助低剂量开会: 小儿乳腺乳癌著者简介： 陈珉珉等内容可：6031剧照：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼低剂量甲状腺髓性乳癌的相关性：基于ALTER01031试验当中的分析方法。会话：胸部著者：天津市医务人员得意博士内容可：6526剧照。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、较小和年龄对安洛替尼低剂量后病症结局的严重影响: ALTER01031的亚组分析方法开会：胸部著者：天津市医务人员得意博士内容可：6527剧照。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA分析方法预测I-IIIA期非小细胞膜膀胱乳癌（NSCLC）病症术后复发: GASTO1035和GASTO1018的结果开会：膀胱乳癌-非小细胞膜渐进-地区性/小细胞膜/小细胞膜/其他胸科乳腺乳癌著者：Si-Yu Wang等内容可：9023剧照：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞膜膀胱乳癌（NSCLC）当中EGFR代谢物激酶胺的新型耐药有助于开会:膀胱乳癌-非小细胞膜乳腺乳癌膀胱乳癌著者简介：赵昕，金结缘，满宇，欧妩媚，梅氏，薛武，杨少，范敏 赵昕、金结缘、满宇、欧妩媚、梅氏、薛武、杨绍、范敏内容可：9528剧照：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验当中当中后半期阿兹海默总生存的替代终点开会：阿兹海默/皮肤乳癌著者：聂润聪，袁书极强，陈元芳，陈英波，周志伟 聂润聪、袁书极强、陈元芳、陈英波、周志伟内容可：10030剧照：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼低剂量复发或乳腺乳癌原发性恶性骨病症的II期学术研究开会： 肉糙著者：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶内容可：11525剧照。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在后半期肉糙病症多线低剂量当中的可用性和。开会：肉糙著者：姚伟涛，王家极强，浙江余姚人，王欣，杜新辉，田志浩，牛晓颖 姚伟涛、王家极强、浙江余姚人、王鑫、杜鑫辉、田志超、牛晓英内容可：11526剧照：414